What is the budget impact of a new treatment or new health technology arriving on the market?
In France, market access for innovative drugs (level I, II & III improvement of medical service rendered having significant impact on health insurance expenditure) involves medico-economic evaluation. In addition to cost-effectiveness analysis (CEA), budget impact analysis (BIA) can be performed, especially since the sustainability of the health insurance system has become a growing concern for all stakeholders. The members of the Giens 2016 round table discussed the contribution of BIA based on a review of the literature on distribution models, the participants' experiences including experience related to the modalities of hospital assessments, and examples from other countries. The round table established recommendations on four elements of interest: 1: the use of BIA from a contractual point of view - between manufacturers and the French Economic Committee for Health Products - during the price negotiations process, and from a prospective point of view within the framework of the annual review of budget expenditures; the definition of the target population and the rhythm of a health product's distribution are also major elements; 2: the interpretation of BIA results in light of CEA results: for what products and at what moment in the life cycle of these products; 3: the integration of the rhythm of a health product's distribution into the BIA; 4: preoccupations about how the level of health product implementation is integrated into the BIA in terms of opportunity cost and organisational quality for the promoter.
EA2694, santé publique : épidémiologie et qualité des soins, CHU de Lille, université de Lille, 59000 Lille, France.
Benoit
B
Dervaux
GlaxoSmithKline, 78163 Marly le Roi, France.
Camille
C
Le Fur
Takeda, immeuble Pacific, 11-13, cours Valmy, 92977 La Défense, France. Electronic address: sophie.dubois@takeda.com.
Sophie
S
Dubois
Sanofi, 94250 Gentilly, France.
Anne
A
Josseran
D020811:Biomedical Technology / Q000191:economics*; D002017:Budgets; D003362:Cost-Benefit Analysis; D005602:France; D006801:Humans; D004364:Pharmaceutical Preparations / Q000191:economics*; D011785:Quality Assurance, Health Care / Q000191:economics*
D004364:Pharmaceutical Preparations
Budget impact; Distribution model; France; Implementation; ONDAM